Zhengda Tianqing Pharmaceutical Co., Ltd. and BioLineRx Co., Ltd. jointly develop hepatitis C treatment drug BL-8030

Recently, biolinerx and Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd signed a foreign license agreement According to the agreement, Zhengda Tianqing will obtain the follow-up development, production and sales license of bl-8030, a hepatitis C treatment drug developed by biolinerx, in mainland China and Hong Kong The product is a second-generation NS3 protease inhibitor, which is currently in the pre clinical research stage Meanwhile, biolinerx will receive about $30 million in upfront fees and is expected to receive sales based royalties Zhengda Tianqing will carry out the follow-up development and production of bl-8030 in accordance with FDA and EMA standards Biolinerx company can obtain and use the later test data of Zhengda Tianqing to carry out commercial and regulatory activities in mainland China and other regions outside Hong Kong Kingneret Savitsky, CEO of biolinerx company, said that Zhengda Tianqing has rich R & D experience in the field of liver disease and is a very powerful partner, and believed that Zhengda Tianqing can rapidly promote the development of bl-8030 with the highest international standards Sun Jian, President of Zhengda Tianqing, said that although bl-8030 is still in the pre clinical research stage, it has the potential to become an important component of the combined treatment of hepatitis C.